NEW YORK (GenomeWeb News) – Newly formed Selah Genomics today announced that it has acquired EnGenCore for an undisclosed amount.

Selah CEO Michael Bolick said in a statement that the purchase of EnGenCore will lead to the development of "molecular and genomic technology at [the University of South Carolina] with an eye toward helping translate this impactful technology to the clinic." The firm's Clinical Genomics Center is located at the GHS Institute for Translational Oncology Research in close proximity to the USC medical school, he noted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.